S
ANTA MONICA, Calif.--UroGenesys and Protein Pathways have formed an alliance to apply Protein Pathways’ bioinformatics technologies to UroGenesys’ database of cancer-associated antigens. The companies expect the combination of their genomics and proteomics expertise to uncover functional information that will guide therapeutic development of UroGenesys’ antigens, as well as identify new product candidates for cancer therapy. Financial terms of the collaboration were not disclosed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.